Ad
related to: genentech free drug applicationscbn.org has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. [18] The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. [24] In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6]
FDA Files Genentech's Supplemental Biologics License Application of Xolair ® (omalizumab) for Chronic Idiopathic Urticaria (CIU) CIU is a skin condition characterized by red, swollen, itchy hives ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. [6]
FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer -- New Personalized Medicine Helped People in ...
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO -- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers --
Mosunetuzumab-axgb was evaluated in GO29781 (NCT02500407), an open-label, multicenter, multi-cohort study. [3] The efficacy population consisted of 90 patients with relapsed or refractory FL who had received at least two prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
Ad
related to: genentech free drug applicationscbn.org has been visited by 10K+ users in the past month